MDMA Investigator's Brochure

MDMA Investigator's Brochure

Investigator’s Brochure SPONSOR Multidisciplinary Association for Psychedelic Studies (MAPS) PRODUCT 3,4-methylenedioxymethamphetamine (MDMA) IND # 063384 DATA CUT-OFF DATE 01 October 2016 EFFECTIVE DATE 21 May 2017 EDITION 9th Edition REPLACES 8th Edition (dated 30 March 2016) MAPS MDMA Investigator’s Brochure U.S. 9th Edition: 21 May 2017 Table of Contents List of Tables ..................................................................................................................... 4 List of Figures .................................................................................................................... 7 List of Abbreviations ........................................................................................................ 7 1.0 Summary ...................................................................................................................... 9 2.0 Introduction ............................................................................................................... 11 3.0 Physical, Chemical, and Pharmaceutical Properties and Formulation ............... 13 4.0 Nonclinical Studies .................................................................................................... 14 4.1 Nonclinical Pharmacology ................................................................................................ 15 4.2 Pharmacology in Animals ................................................................................................. 15 4.2.1 Pharmacokinetics in Animals ....................................................................................... 15 4.2.2 Pharmacodynamics in Animals .................................................................................... 17 4.2.2.1 Stable Effects on Gene Expression in Animals .................................................... 18 4.2.2.2 Immunological Effects in Animals ....................................................................... 19 4.2.2.3 Thermoregulatory Effects in Animals................................................................... 20 4.2.2.4 Cardiovascular Effects in Animals ....................................................................... 20 4.2.2.5 Osmoregulatory Effects in Animals ...................................................................... 20 4.2.2.6 Neurobiological Effects in Animals ...................................................................... 21 4.2.2.7 Neuropsychological Effects in Animals ............................................................... 22 4.3 Physiological Effects in Epidemiological Settings ........................................................... 23 4.3.1 Immunological Effects ................................................................................................. 23 4.3.2 Thermoregulatory Effects ............................................................................................ 24 4.3.3 Cardiovascular Effects ................................................................................................. 24 4.3.4 Osmoregulatory Effects ................................................................................................ 24 4.3.5 Neurobiological Effects ................................................................................................ 24 4.3.6 Neuropsychological Effects ......................................................................................... 26 4.4 Toxicology in Animals and Epidemiological Settings ..................................................... 27 4.4.1 Single Dose Studies in Animals ................................................................................... 27 4.4.2 Repeated Dose Studies in Animals .............................................................................. 28 4.4.3 Genotoxicity ................................................................................................................. 28 4.4.4 Carcinogenicity ............................................................................................................ 28 4.4.5 Reproductive and Developmental Toxicity .................................................................. 29 4.4.6 Hyperthermia ................................................................................................................ 31 4.4.7 Cardiovascular Toxicity ............................................................................................... 32 4.4.8 Hyponatremia ............................................................................................................... 32 4.4.9 Hepatotoxicity .............................................................................................................. 33 4.4.10 Neurotoxicity .............................................................................................................. 33 4.5 Serious Reports of Incidents, Mortality, and Morbidity in Animals and Epidemiological Settings ......................................................................................................... 35 4.6 Abuse Potential in Nonclinical Studies ............................................................................ 41 5.0 Effects in Humans in Clinical Settings .................................................................... 42 5.1 History of Use in Clinical Settings .................................................................................... 42 5.2 Pharmacology in Humans ................................................................................................. 44 5.2.1 Pharmacokinetics ......................................................................................................... 44 5.2.2 Pharmacodynamics....................................................................................................... 46 5.3 Safety of MDMA in Humans ............................................................................................ 49 5.3.1 Reproductive and Developmental ................................................................................ 50 5.3.2 Immunological Effects ................................................................................................. 50 5.3.3 Thermoregulatory Effects ............................................................................................ 51 5.3.4 Cardiovascular Effects ................................................................................................. 54 Page 2 of 187 MAPS MDMA Investigator’s Brochure U.S. 9th Edition: 21 May 2017 5.3.5 Osmoregulatory Effects ................................................................................................ 64 5.3.6 Hepatic Effects ............................................................................................................. 64 5.3.7 Neurobiological Effects ................................................................................................ 65 5.3.8 Neuropsychological Effects ......................................................................................... 66 5.3.8.1 Cognitive Function................................................................................................ 67 5.3.8.2 Perceptual Effects ................................................................................................. 69 5.3.8.3 Social Effects ........................................................................................................ 70 5.3.8.4 Emotional Effects.................................................................................................. 71 5.3.8.5 Suicidal Ideation, Behavior, and Depression ........................................................ 72 5.3.9 Adverse Events ............................................................................................................. 82 5.3.9.1 Commonly Reported Adverse Events ................................................................... 82 5.3.9.2 Adverse Events ................................................................................................... 106 5.3.9.3 Serious Adverse Events ...................................................................................... 120 5.3.10 Abuse Potential ........................................................................................................ 122 5.4 5.4 Efficacy of MDMA Across Populations ................................................................... 131 5.4.1 PTSD .......................................................................................................................... 131 5.4.2 Social Anxiety in Autistic Adults ............................................................................... 132 5.4.3 Anxiety Associated with Life-Threatening Illness ..................................................... 133 6.0 Summary of Data and Guidance for the Investigator ......................................... 133 6.1 Pharmacology .................................................................................................................. 133 6.2 Toxicology ........................................................................................................................ 134 6.3 Physiological Effects ........................................................................................................ 136 6.3.1 Immunological Effects ............................................................................................... 137 6.3.2 Hepatic Effects ........................................................................................................... 138 6.4 Suicidal Ideation, Behavior, and Depression

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    187 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us